Jan Skvarka's most recent trade in Zentalis Pharmaceuticals Inc was a trade of 60,000 Common Stock done at an average price of $1.7 . Disclosure was reported to the exchange on Jan. 31, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Zentalis Pharmaceuticals Inc | Jan Skvarka | Director | Purchase of securities on an exchange or from another person at price $ 1.72 per share. | 31 Jan 2025 | 60,000 | 149,551 | - | 1.7 | 103,446 | Common Stock |
Zentalis Pharmaceuticals Inc | Jan Skvarka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 41,581 | 89,551 | - | 0 | Common Stock | |
Monte Rosa Therapeutics Inc | Jan Skvarka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 22,100 | 22,100 | - | - | Stock Option (Right to Buy) | |
Zentalis Pharmaceuticals Inc | Jan Skvarka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 16,364 | 52,970 | - | 0 | Common Stock | |
Monte Rosa Therapeutics Inc | Jan Skvarka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 20,500 | 20,500 | - | - | Stock Option (Right to Buy) | |
Monte Rosa Therapeutics Inc | Jan Skvarka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2023 | 41,000 | 41,000 | - | - | Stock Option (Right to Buy) | |
Zentalis Pharmaceuticals Inc | Jan Skvarka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2022 | 36,606 | 36,606 | - | 0 | Common Stock |